The aryl hydrocarbon receptor and its xenobiotic ligands: A fundamental trigger for cardiovascular diseases

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 13, Issue 2, 2003, Pages 104-113

  Savouret, J F ^a   Berdeaux, A ^b   Casper, R F ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Aryl hydrocarbon receptor; Atherosclerosis; Benzopyrene; Resveratrol; Smoking; TCDD

Indexed keywords

AROMATIC HYDROCARBON; LIGAND; RESVERATROL; AROMATIC HYDROCARBON RECEPTOR; STILBENE DERIVATIVE; XENOBIOTIC AGENT;

ALCOHOL CONSUMPTION; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; GENE SEQUENCE; HUMAN; LIPID PEROXIDATION; POLLUTANT; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SEQUENCE ANALYSIS; SMOKING; XENOBIOTIC METABOLISM; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; TOBACCO;

NICOTIANA TABACUM;

CARDIOVASCULAR DISEASES; HUMANS; LIGANDS; RECEPTORS, ARYL HYDROCARBON; SMOKING; STILBENES; TOBACCO; XENOBIOTICS;

EID: 0642307077     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(03)80026-1     Document Type: Review

References (86)

1. Greaves DR, Channon KM (2002) Inflammation and immune responses in atherosclerosis. Trends Immunol 23: 535-541
2. Poller W, Fechner H, Noutsias M, Tschoepe C, Schultheiss HP (2002) Highly variable expression of virus receptors in the human cardiovascular system Implications for cardiotropic viral infections and gene therapy. Z Kardiol 91: 978-991
3. Vercellotti GM (2001) Overview of infections and cardiovascular diseases. J Allergy Clin Immunol 108: S117-120
4. Rowlands JC, Gustafsson JA (1997) Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 27: 109-134
5. Muto H, Takizawa Y (1989) Dioxins in cigarette smoke. Arch Environ Health 44: 171-174
6. Bock KW (1994) Aryl hydrocarbon or dioxin receptor: biologic and toxic responses. Rev Physiol Biochem Pharmacol 125: 1-42
7. Toborek M, Barger SW, Mattson MP, Espandiari P, Robertson LW, Hennig B (1995) Exposure to polychlorinated biphenyls causes endothelial cell dysfunction. J Biochem Toxicol 10: 219-226
8. Kleman M, Gustafsson JA (1996) Interactions of procarcinogenic heterocyclic amines and indolocarbazoles with the dioxin receptor. Biol Chem 377: 741-762
9. Nebert DW, Puga A, Vasiliou V (1993) Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. Ann N Y Acad Sci 685: 624-640
10. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Alexandrov K, Rojas M, Saracci R, Giuntini C (1992) Carcinogen metabolism in human lung tissues and the effect of tobacco smoking: results from a case-control multicenter study on lung cancer patients. Environ Health Perspect 98: 119-124
11. Kerkvliet NI (1995) Immunological effects of chlorinated dibenzo-p-dioxins. Environ Health Perspect 103 (Suppl 9): 47-53
12. Yao Y, Hoffer A, Chang CY, Puga A (1995) Dioxin activates HIV-1 gene expression by an oxidative stress pathway requiring a functional cytochrome P450 CYP1A1 enzyme. Environ Health Perspect 103: 366-371
13. Burleson GR, Lebrec H, Yang YG, Ibanes JD, Pennington KN, Birnbaum LS (1996) Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on influenza virus host resistance in mice. Fundam Appl Toxicol 29: 40-47
14. Zenzes MT (2000) Smoking and reproduction: gene damage to human gametes and embryos. Hum Reprod Update 6: 122-131
15. Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87: 18-24
16. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, Boobis AR, Raunio H (1996) Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 51: 403-411
17. Park JY, Shigenaga MK, Ames BN (1996) Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci USA 93: 2322-2327
18. Savouret JF, Antenos M, Quesne M, Xu J, Milgrom E, Casper RF (2001) 7-ketocholesterol is an endogenous modulator for the Aryl hydrocarbon Receptor. J Biol Chem 276: 3054-3059
19. Song W, Pierce WM Jr, Prough RA, Redinger RN (1991) Characteristics of cholesterol 7 alpha-hydroxylase and 7 alpha-hydroxycholesterol hydroxylase activities of rodent liver. Biochem Pharmacol 41: 1439-1447
20. Song W, Pierce WM Jr, Saeki Y, Redinger RN, Prough RA (1996) Endogenous 7-oxocholesterol is an enzymatic product: characterization of 7 alpha-hydroxycholesterol dehydrogenase activity of hamster liver microsomes. Arch Biochem Biophys 328: 272-282
21. Hengstler JG, Van der Burg B, Steinberg P, Oesch F (1999) Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31: 917-970
22. Mattison DR, Thorgeirsson SS (1978) Smoking and industrial pollution, and their effects on menopause and ovarian cancer. Lancet 1: 187-188
23. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21: 7435-7451
24. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430-432
25. Zhang YJ, Weksler BB, Wang L, Schwartz J, Santella RM (1998) Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. Atherosclerosis 140: 325-331
26. Crawford RB, Holsapple MP, Kaminski NE (1997) Leukocyte activation induces aryl hydrocarbon receptor up-regulation, DNA binding, and increased Cyp1a1 expression in the absence of exogenous ligand. Mol Pharmacol 52: 921-927
27. Stegeman JJ, Hahn ME, Weisbrod R, Woodin BR, Joy JS, Najibi S, Cohen RA (1995) Induction of cytochrome P4501A1 by aryl hydrocarbon receptor agonists in porcine aorta endothelial cells in culture and cytochrome P4501A1 activity in intact cells. Mol Pharmacol 47: 296-306
28. Annas A, Granberg AL, Brittebo EB (2000) Differential response of cultured human umbilical vein and artery endothelial cells to Ah receptor agonist treatment: CYP-dependent activation of food and environmental mutagens. Toxicol Appl Pharmacol 169: 94-101
29. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924
30. Bombick DW, Matsumura F, Madhukar BV (1984) TCDD (2,3,7,8- tetrachlorodibenzo-p-dioxin) causes reduction in the low density lipoprotein (LDL) receptor activities in the hepatic plasma membrane of the guinea pig and rat. Biochem Biophys Res Commun 118: 548-554
31. Rifkind AB, Gannon M, Gross SS (1990) Arachidonic acid metabolism by dioxin-induced cytochrome P-450: a new hypothesis on the role of P-450 in dioxin toxicity. Biochem Biophys Res Commun 172: 1180-1188
32. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE (2002) Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 162: 391-397
33. Zhao D, Pritts EA, Chao VA, Savouret JF, Taylor RN (2002) Dioxin stimulates RANTES expression in an in-vitro model of endometriosis. Mol Hum Reprod 8: 849-854
34. Fan F, Yan B, Wood G, Viluksela M, Rozman KK (1997) Cytokines (IL-1beta and TNFalpha) in relation to biochemical and immunological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicology 116: 9-16
35. Yin H, Li Y, Sutter TR (1994) Dioxin-enhanced expression of interleukin-1 beta in human epidermal keratinocytes: potential role in the modulation of immune and inflammatory responses. Exp Clin Immunogenet 11: 128-135
36. Charles GD, Shiverick KT (1997) 2,3,7,8-Tetrachlorodibenzo-p-dioxin increases mRNA levels for interleukin-1beta, urokinase plasminogen activator, and tumor necrosis factor-alpha in human uterine endometrial adenocarcinoma RL95-2 cells. Biochem Biophys Res Commun 238: 338-342
37. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM (1996) Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 93: 1334-1338
38. Lindsherg PJ (1996) ICAM-1 as a potential target for treatments blocking the host response in stroke. Keio J Med 45: 254-261; discussion 261-262
39. Watanabe T, Fan J (1998) Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol 66 (Suppl 1): S45-53; discussion S55
40. Fukaya T, Sugawara J, Yoshida H, Murakami T, Yajima A (1999) Intercellular adhesion molecule-1 and hepatocyte growth factor in human endometriosis: original investigation and a review of literature. Gynecol Obstet Invest 47 (Suppl 1): 11-16; discussion 16-17
41. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, Pettigrew KD, Hallenbeck JM (1998) Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 29: 1405-1410
42. Shen Y, Rattan V, Sultana C, Kalra VK (1996) Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 270: H1624-1633
43. Gonzalez S, Hards J, van Eeden S, Hogg JC (1996) The expression of adhesion molecules in cigarette smoke-induced airways obstruction. Eur Respir J 9: 1995-2001
44. Kamanna VS, Pai R, Ha H, Kirschenbaum MA, Roh DD (1999) Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int 55: 2192-2202
45. Khan BV, Parthasarathy SS, Alexander RW, Medford RM (1995) Modified low density lipoprotein and its constituents augment cytokine- activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95: 1262-1270
46. Amberger A, Maczek C, Jurgens G, Michaelis D, Schett G, Trieb K, Eberl T, Jindal S, Xu Q, Wick G (1997) Co-expression of ICAM-1, VCAM-1, ELAM-1 and Hsp60 in human arterial and venous endothelial cells in response to cytokines and oxidized low- density lipoproteins. Cell Stress Chaperones 2: 94-103
47. Roebuck KA (1999) Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med 4: 223-230
48. Hutchins D, Steel CM (1994) Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 58: 80-84
49. Heinecke JW (1999) Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 133: 321-325
50. Gollapudi S, Kim CH, Patel A, Sindhu R, Gupta S (1996) Dioxin activates human immunodeficiency virus-1 expression in chronically infected promonocytic U1 cells by enhancing NF-kappa B activity and production of tumor necrosis factor-alpha. Biochem Biophys Res Commun 226: 889-894
51. Masten SA, Shiverick KT (1996) Characterization of the aryl hydrocarbon receptor complex in human B lymphocytes: evidence for a distinct nuclear DNA-binding form. Arch Biochem Biophys 336: 297-308
52. Safe S (2001) Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120: 1-7
53. Safe S, Wang F, Porter W, Duan R, McDougal A (1998) Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett 102-103: 343-347
54. Glass CK (2001) Potential roles of the peroxisome proliferator-activated receptor-gamma in macrophage biology and atherosclerosis. J Endocrinol 169: 461-464
55. Ricote M, Welch JS, Glass CK (2000) Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 54: 275-280
56. Alexander DL, Ganem LG, Fernandez-Salguero P, Gonzalez F, Jefcoate CR (1998) Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. J Cell Sci 111: 3311-3322
57. de Lorgeril M, Salen P, Paillard F, Laporte F, Boucher F, de Leiris J (2002) Mediterranean diet and the French paradox: two distinct biogeographic concepts for one consolidated scientific theory on the role of nutrition in coronary heart disease. Cardiovasc Res 54: 503-515
58. de Lorgeril M, Salen P (2001) Mediterranean type of diet for the prevention of coronary heart disease. A global perspective from the seven countries study to the most recent dietary trials. Int J Vitam Nutr Res 71: 166-172
59. de Lorgeril M, Salen P, Martin JL, Boucher F, Paillard F, de Leiris J (2002) Wine drinking and risks of cardiovascular complications after recent acute myocardial infarction. Circulation 106: 1465-1469
60. Constant J (1997) Alcohol, ischemic heart disease, and the French paradox. Coron Artery Dis 8: 645-649
61. Criqui MH, Ringel BL (1994) Does diet or alcohol explain the French paradox? Lancet 344: 1719-1723
62. Renaud S, de Lorgeril M (1992) Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526
63. Rimm EB (1996) Alcohol consumption and coronary heart disease: good habits may be more important than just good wine. Am J Epidemiol 143: 1094-1098; discussion 1099
64. Soleas GJ, Diamandis EP, Goldberg DM (1997) Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal 11: 287-313
65. Nonomura S, Kanagawa H, Makimoto A (1963) Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum Cuspidatum SIEB et ZUCC). Yakugaku Zasshi 83: 983-988
66. Siemann EH, Creasy LL (1992) Concentration of the Phytoalexin resveratrol in wine. Am J Enol Vitic 43: 49-52
67. Goldberg D, Tsang E, Karumanchiri A, Diamandis E, Soleas G, Ng E (1996) Method to assay the concentrations of phenolic constituents of biological interest in wines. Anal Chem 68: 1688-1694
68. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220
69. Savouret JF, Quesne, M (2002) Resveratrol and cancer: a review. Biomed Pharmacother 56: 84-87
70. Gusman J, Malonne H, Atassi G (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117
71. Soleas GJ, Diamandis EP, Goldberg DM (1997) Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30: 91-113
72. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, Savouret JF (1999) Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56: 784-790
73. Wilhelmsson A, Whitelaw ML, Gustafsson JA, Poellinger L (1994) Agonistic and antagonistic effects of alpha-naphthoflavone on dioxin receptor function. Role of the basic region helix-loop-helix dioxin receptor partner factor Arnt. J Biol Chem 269: 19028-19033
74. Bjeldanes LF, Kim JY, Grose KR, Bartholomew JC, Bradfield CA (1991) Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8- tetrachlorodibenzo-p-dioxin. Proc Natl Acad Sci U S A 88: 9543-9547
75. Gerritsen ME, Carley WW, Ranges GE, Shen CP, Phan SA, Ligon GF, Perry CA (1995) Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am J Pathol 147: 278-292
76. Kobuchi H, Roy S, Sen CK, Nguyen HG, Packer L (1999) Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am J Physiol 277: C403-C411
77. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, Corsi MM, Bonfrate M, Ferrara F, De Caterina R, Giovannini L, Bertelli A (1998) Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 68: 1208-1214
78. Bertelli A, Bertelli AA, Gozzini A, Giovannini L (1998) Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 24: 133-138
79. Zhu BT, Liehr JG (1994) Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol Appl Pharmacol 125: 149-158
80. Koley AP, Buters JT, Robinson RC, Markowitz A, Friedman FK (1997) Differential mechanisms of cytochrome P450 inhibition and activation by alpha-naphthoflavone. J Biol Chem 272: 3149-3152
81. Collman GW, Lundgren K, Shore D, Thompson CL, Lucier GW (1986) Effects of alpha-naphthoflavone on levels of sister chromatid exchanges in lymphocytes from active and passive cigarette smokers: dose-response relationships. Cancer Res 46: 6452-6455
82. Gehm BD, McAndrews JM, Chien PY, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94: 14138-14143
83. Lu R, Serrero G (1999) Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179: 297-304
84. Bowers JL, Tyulmenkov V.V., Jernigan SC, Klinge CM (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667
85. Kreuzer PE, Csanady GA, Baur C, Kessler W, Papke O, Greim H, Fuser JG (1997) 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition. Arch Toxicol 71: 383-400
86. Aligne CA, Stoddard JJ (1997) Tobacco and children. An economic evaluation of the medical effects of parental smoking. Arch Pediatr Adolesc Med 151: 648-653